The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma Second patient maintains an ongoing complete ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results